ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT06136741

Public ClinicalTrials.gov record NCT06136741. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 10:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

Study identification

NCT ID
NCT06136741
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Nektar Therapeutics
Industry
Enrollment
396 participants

Conditions and interventions

Conditions

Not listed

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 14, 2023
Primary completion
May 5, 2025
Completion
Dec 30, 2026
Last update posted
May 7, 2026

2023 – 2026

United States locations

U.S. sites
28
U.S. states
13
U.S. cities
25
Facility City State ZIP Site status
Nektar Investigative Site Bryant Arkansas 72022
Nektar Investigative Site Fountain Valley California 92708
Nektar Investigative Site Los Angeles California 90017
Nektar Investigative Site Los Angeles California 90025
Nektar Investigative Site Los Angeles California 90057
Nektar Investigative Site Santa Monica California 90404
Nektar Investigative Site Hialeah Florida 33016
Nektar Investigative Site Hollywood Florida 33021
Nektar Investigative Site Miami Florida 33173
Nektar Investigative Site Miami Lakes Florida 33014
Nektar Investigative Site St. Petersburg Florida 33705
Nektar Investigative Site Tampa Florida 33615
Nektar Investigative Site Marietta Georgia 30060
Nektar Investigative Site Clarksville Indiana 47129
Nektar Investigative Site Indianapolis Indiana 46202
Nektar Investigative Site Louisville Kentucky 40241
Nektar Investigative Site Flint Michigan 48532
Nektar Investigative Site Troy Michigan 48084
Nektar Investigative Site Las Vegas Nevada 89106
Nektar Investigative Site New York New York 10075
Nektar Investigative Site Fairborn Ohio 45324
Nektar Investigative Site Mayfield Heights Ohio 44124
Nektar Investigative Site Murfreesboro Tennessee 37130
Nektar Investigative Site Bellaire Texas 77401
Nektar Investigative Site Cypress Texas 77429
Nektar Investigative Site Frisco Texas 75034
Nektar Investigative Site Spokane Washington 99202-1461
Nektar Investigative Site Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06136741, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06136741 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →